Coultreon
Founded 2025 · 32 employees on LinkedIn · 10 known investors
Find your way into Coultreon
891 people in our graph share verified history with the Coultreon team — schools, employers, funds. One of them is your warm intro.
René Kuijtenunlockedknows Joost Kolkman · together at Utrecht University (overlapped)
knows the team · via Johnson & Johnson
knows the team · via UCL
×3knows the team · via Imperial College London
knows the team · via Galapagos
knows the team · via Ablynx
Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.
Founders & leadership
PR
Pierre RaboissoninChief Executive Officer Chief Scientific Officer Co-founderPierre Raboisson is a pharmacist and Ph.D. holder with over 25 years in biopharmaceutical development; he founded Coultreon and previously led drug discovery efforts contributing to multiple approved therapeutics including Simeprevir, and built R&D organizations across Europe and the United States.
MD
Marie De VulderinChief Legal Officer Co-founderShe holds an Advanced Master's degree in Intellectual Property Rights and ICT Law from the University of Leuven and has background in corporate law and contract negotiation.
GP
Guy PeetersinChief Financial Officer Co-founderHe brings over 20 years of finance leadership experience in biotech and pharmaceuticals, including roles as SVP of Finance, Procurement & Facilities at Galapagos, Senior Finance Director at Janssen Germany, and 15 years in finance positions at Johnson & Johnson; he holds a Master's degree in Applied Economics from the University of Antwerp and a degree in International Taxation from KU Leuven.
JG
John-Paul GallivaninHead of Development Co-founderHead of Development and co-founder of Coultreon. Gallivan has held roles in both small biotech and large pharmaceutical companies, with experience in drug development and commercialization across oncology and virology programs.
FK
Fabrice KolbinHead of Immunology Co-founderHe brings over two decades of drug discovery experience from roles at Galapagos (2019–2025), Roche (2015–2019), and Novartis (2006–2015), where he led immunology and oncology programs and contributed to the development of multiple approved therapeutics including complement-targeted antibodies and inhibitors.
PP
Pieter PeetersinOperating & Technology Officer Co-founder
FG
François GonzalvezinCo-founderHe brings two decades of experience in oncology and immuno-oncology drug discovery, including leading programs from target identification through phase 1 development.
SV
Sandrine VendevilleinCo-founderShe previously co-invented Simeprevir, an approved HCV treatment, and led development of multiple clinical-stage therapeutic candidates including an HCV nucleoside inhibitor, an RSV fusion inhibitor, and an HBV capsid assembly modulator. She has expertise in medicinal chemistry, drug metabolism, and intellectual property strategy, with over 50 patents and publications.
JK
Joost KolkmaninCo-founderJoost Kolkman has over 20 years of experience in drug discovery and development, including team leadership, collaboration with academic institutions and contract research organizations, and technical assessment of biotech platforms and assets. He co-founded Coultreon to advance small and large molecule therapeutic programs across multiple disease areas.
Investors · 10
Longwood FundBoston
Sofinnova VenturesMenlo Park · $100K – $15M
BAM ElevatereportedChicago
Finchley Healthcare VenturesreportedMontreal
Forbionreported · 2 sourcesNaarden
Luma GroupreportedNew York
Novo Holdingsreported · 2 sourcesCopenhagen · $1.1M – $54M
Samsara BioCapitalreportedPalo Alto
Also in the syndicate · 2
GalapagosRegeneron Ventures
Funding
SEC filings, press & company announcements$125M disclosed across 1 round · 2026
- $125MSeries AApr 2026 · 3 sources
Sofinnova Investments (lead), Balyasny Asset Management, Finchley Healthcare Ventures, Forbion, Galapagos, Longwood Fund, Luma Group, Novo Holdings, Regeneron Ventures, Samsara BioCapital
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 2
by search overlapBioworld3 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Day One Biopharmaceuticals3 shared keywordsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
Companies competing with Coultreon for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Coultreon do?
- Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.
- Who founded Coultreon?
- Coultreon was founded by Pierre Raboisson, Marie De Vulder, Guy Peeters, John-Paul Gallivan, Fabrice Kolb, Pieter Peeters, François Gonzalvez, Sandrine Vendeville, Joost Kolkman in 2025.
- Who are Coultreon's investors?
- Coultreon's investors include Longwood Fund, Sofinnova Ventures, BAM Elevate, Finchley Healthcare Ventures, Forbion, Luma Group, Novo Holdings, Samsara BioCapital.
- How much funding has Coultreon raised?
- Coultreon has disclosed $125M raised across 1 round.